Malin has decided to target the funding needs of privately held early-stage life sciences business.

The Elan gene pool delivers once again. It would be wrong to suggest that the business – since subsumed into generics and over-the-counter specialist (...)

Former Elan chief executive Kelly Martin (pictured) and chairman Bob Ingram, who sold the Irish stock market stalwart to Perrigo for $8.6 billion in 2013, will sit on the board of Malin

Malin, an Irish company set up by a number of former Elan executives to invest in privately held life science assets, said it plans to raise between €(...)

While Royalty Pharma boosted its unsolicited offer to as much as $15.50 a share this month, at least five analysts covering Dublin-based Elan see the stock falling if that bid disappears

Elan shareholders risk losing $2 billion by listening to the company’s board and rejecting Royalty Pharma’s takeover bid, according to market analysts(...)

The idea started when Pablo Legorreta came across an innovative scheme pioneered by Paine Webber bankers.

It may be Dublin-based, but Royalty Pharma was unknown even here until it announced its interest in acquiring Elan, Ireland’s largest indigenous pharm(...)

Elan chief executive Kelly Martin: “There’s always a Plan B and a C.” Photograph: Alan Betson

Irish drug-maker Elan will lay out an alternative strategy if shareholders reject a string of planned deals and thereby make a bid from a US-based inv(...)